Journal
VIRUSES-BASEL
Volume 13, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/v13010108
Keywords
mosquito-borne viral diseases; antiviral drugs; small molecules; arboviral transmission cycle; dengue virus; Zika virus; Aedes aegypti
Categories
Funding
- National Institutes of Health [R01AI141532]
- Bloomberg Philanthropies
Ask authors/readers for more resources
Mosquito-borne arthropod-borne viruses are important human pathogens with significant global morbidity and mortality, highlighting the need for safe and effective vaccines, therapeutics, and vector-control approaches. Disrupting the virus lifecycle in mosquitoes is a key strategy for combating these diseases, with proposed methods including genetically modified mosquitoes or infection with the symbiotic bacterium Wolbachia.
Mosquito-borne arthropod-borne viruses (arboviruses) such as the dengue virus (DENV), Zika virus (ZIKV), and chikungunya virus (CHIKV) are important human pathogens that are responsible for significant global morbidity and mortality. The recent emergence and re-emergence of mosquito-borne viral diseases (MBVDs) highlight the urgent need for safe and effective vaccines, therapeutics, and vector-control approaches to prevent MBVD outbreaks. In nature, arboviruses circulate between vertebrate hosts and arthropod vectors; therefore, disrupting the virus lifecycle in mosquitoes is a major approach for combating MBVDs. Several strategies were proposed to render mosquitoes that are refractory to arboviral infection, for example, those involving the generation of genetically modified mosquitoes or infection with the symbiotic bacterium Wolbachia. Due to the recent development of high-throughput screening methods, an increasing number of drugs with inhibitory effects on mosquito-borne arboviruses in mammalian cells were identified. These antivirals are useful resources that can impede the circulation of arboviruses between arthropods and humans by either rendering viruses more vulnerable in humans or suppressing viral infection by reducing the expression of host factors in mosquitoes. In this review, we summarize recent advances in small-molecule antiarboviral drugs in mammalian and mosquito cells, and discuss how to use these antivirals to block the transmission of MBVDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available